This low-price pharma stock has jumped over 300 per cent in one year
The pharma sector proved to be the most crucial sector in 2020 as well as in 2021, owing to the pandemic-related situation.
While BSE Healthcare index was up by 59 per cent, Nifty gained around 61.17 per cent in the last one year. Marksans Pharma managed to catch investors' attention when the pharma stocks were buzzing around.
In the third quarter of FY21, Marksans Pharma delivered strong growth in revenue and margins. Also, the company has witnessed improvement in financial ratios during the same quarter. The net sales in December 2020 showed a gain of 24.58 per cent on a YoY basis whereas the quarterly net profit surged substantially by 99.39 per cent on a YoY basis. The stock has delivered over 23 per cent return in the year 2021 while it gained over 38.9 per cent over the last one month. In a span of one year, the stock is up by 310.9 per cent.
Marksans Pharma, headquartered in Mumbai (India), is a global pharmaceutical company. It is actively engaged in research & development and offer contract research as well as manufacturing services (CRAMS) to global pharmaceutical companies. The company has a market capitalisation of Rs 3,014 crore and is currently trading at Rs 75.25. The stock traded at Rs 18.40 during the same period last year.